Titan Pharma (Earnings Tk. 60 million, 15 million shares, EPS Tk. 4.00, P/E 15x, Share price Tk. 60.00) acquires Novelty Labs (Earnings Tk. 20 million, 10 million shares, EPS Tk. 2.00, P/E 10x, Share price Tk. 20.00) by issuing 1 Titan share for every 2.5 Novelty shares. Assuming zero synergies, what is the combined post-merger EPS and is it accretive or dilutive to Titan's original shareholders?
- ATk. 3.80 per share (-5.00% Dilutive)
- BTk. 4.21 per share (+5.25% Accretive)
- CTk. 4.00 per share (Neutral)
- DTk. 4.50 per share (+12.50% Accretive)